Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Dollar edges down, set for weekly loss; Aussie and Kiwi rise

11/27/2020 | 04:03am EST

* Graphic: World FX rates in 2020 https://tmsnrt.rs/2RBWI5E

LONDON, Sept 7 (Reuters) - The dollar fell in early London trading on Friday and was on track for a weekly loss against a basket of currencies, even as the equity market rally ran out of steam as sentiment was hurt by doubts about AstraZeneca's COVID-19 vaccine.

The dollar has fallen more than 2.2% so far this month as global market sentiment has surged on Joe Biden's U.S. election victory and news of progress in the development of COVID-19 vaccines, lessening demand for the safe-haven currency.

But sentiment became more mixed after several scientists raised doubts about the success rate for the vaccine developed by British drugmaker AstraZeneca.

AstraZeneca had said on Monday that its vaccine was 70% effective in pivotal trials, and could be up to 90% effective - the latest in a slew of positive vaccine announcements which had boosted investor confidence.

"Virus and vaccine news remain the main catalysts for markets as the US calendar is empty until Monday," ING strategists wrote in a note to clients.

"All in all, risk sentiment still appears in stabilization mode, and the dollar may keep oscillating around 2-year lows (the 92.00 level for DXY) today due to the lack of clear catalysts and reduced trading volumes," they said.

At 0831 GMT, the dollar was at 91.953 versus a basket of currencies, down 0.1% on the day and close to its lowest in three months. Market price-action was limited on Thursday by the Thanksgiving holiday in the United States, which will be operating on reduced trading hours on Friday.

The Australian dollar - a liquid proxy for risk - hit its highest in nearly three months in early London trading and was up 0.2% at 0.7375 at 0834 GMT.

Australia's second-largest state, Victoria, which was once the country's COVID-19 hotspot, said on Friday that it has gone 28 days without detecting new infections.

The Kiwi dollar, which is having its best month since late 2013, was up 0.1% on the day at 0.7019.

"Clearly, the biggest single risk for financial markets now is the failure of vaccines being rolled out smoothly in Q1 2021," wrote MUFG strategist Derek Halpenny.

"The other key risk that also continues to be ignored is the ongoing surge in COVID infections and deaths in the US," he said, adding that if President-elect Joe Biden brings in new lockdown restrictions while the rest of the world is recovering next year then that provide a further reason to sell the dollar.

Dollar-yen was down 0.2% at 104.03 at 0836 GMT. China's offshore yuan was on track for its first week of net losses versus the dollar this month.

The euro was up 0.1% at $1.1925, having shown little reaction to downbeat comments from the European Central Bank's chief economist Philip Lane on Thursday.

Elsewhere, the pound was steady at $1.3369 as UK investors watched Brexit negotiations for signs of progress. The European Union's chief negotiator said he would travel to London later on Friday to continue talks. Euro-sterling was steady at 89.22 pence per euro at 0844 GMT.

Bitcoin, which stabilised overnight after wiping off more than a week's worth of gains on Thursday, was starting to fall again in early London trading, but less steeply than in the previous session. (Reporting by Elizabeth Howcroft; Editing by Simon Cameron-Moore)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.78% 7722 Delayed Quote.4.62%
AUSTRALIAN DOLLAR / CANADIAN DOLLAR (AUD/CAD) 0.00% 0.97956 Delayed Quote.0.30%
AUSTRALIAN DOLLAR / JAPANESE YEN (AUD/JPY) 0.25% 79.915 Delayed Quote.0.55%
AUSTRALIAN DOLLAR / NEW ZEALAND DOLLAR (AUD/NZD) 0.17% 1.08185 Delayed Quote.0.88%
AUSTRALIAN DOLLAR / SWISS FRANC (AUD/CHF) -0.10% 0.684 Delayed Quote.0.72%
AUSTRALIAN DOLLAR / US DOLLAR (AUD/USD) 0.09% 0.76909 Delayed Quote.-0.14%
BITCOIN - EURO -0.55% 30195.16 Real-time Quote.29.20%
BRITISH POUND / AUSTRALIAN DOLLAR (GBP/AUD) 0.24% 1.77134 Delayed Quote.-0.53%
EURO / AUSTRALIAN DOLLAR (EUR/AUD) 0.29% 1.57583 Delayed Quote.-1.03%
EURO / BRITISH POUND (EUR/GBP) 0.06% 0.88956 Delayed Quote.-0.48%
UNITED STATES DOLLAR (B) / CHINESE YUAN IN HONG KONG (USD/CNH) -0.27% 6.4754 Delayed Quote.-0.23%
US DOLLAR / JAPANESE YEN (USD/JPY) 0.19% 103.903 Delayed Quote.0.70%
All news about ASTRAZENECA PLC
01:57pPeru says Sinopharm, Pfizer seek approval for their COVID-19 vaccines
01:43pASTRAZENECA : India to start COVID vaccine exports on Wednesday
01:37pASTRAZENECA : India to start COVID vaccine exports on Wednesday
11:35aBrussels targets vaccinating at least 70% of EU adults by summer
07:45aASTRAZENECA : India's homegrown vaccine developer warns some to avoid shot
07:31aJapan has pre-ordered COVID-19 vaccine doses for more than four times its pop..
06:44aSputnik-AstraZeneca vaccine trials to start in February, says R-Pharm
06:38aPhilippines to buy 20 million Moderna vaccine doses as COVID-19 cases rise
05:00aASTRAZENECA : Thailand defends royal company's role in vaccine strategy
04:39aASTRAZENECA : Thailand defends royal company's role in vaccine strategy
More news
Financials (USD)
Sales 2020 26 399 M - -
Net income 2020 2 970 M - -
Net Debt 2020 13 223 M - -
P/E ratio 2020 40,8x
Yield 2020 2,71%
Capitalization 137 B 137 B -
EV / Sales 2020 5,68x
EV / Sales 2021 4,91x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 126,16 $
Last Close Price 104,06 $
Spread / Highest target 50,0%
Spread / Average Target 21,2%
Spread / Lowest Target -19,2%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG1.93%303 276
NOVARTIS AG1.65%217 178
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993